USPTO serial 97042228
MORPHOSYS
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Jun 6, 2023
- Examiner
- WANG, YUAN YUAN
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with MORPHOSYS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Maury M. Tepper, III
Maury M. Tepper, III Tepper & Eyster, PLLC3724 Benson DriveRaleigh, NC 27609United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 001 | reagents for scientific and medical research for use in the research and production of small molecule pharmaceuticals; active pharmaceutical ingredients, namely, antibodies, proteins and small molecules for use in the manufacture of pharmaceuticals, biopharmaceuticals, vaccines, and finished drug products; antibodies for use in the manufacture of active ingredients of pharmaceuticals and vaccines | ACTIVE | — |
| 005 | pharmaceutical preparations for the treatment of diseases that involve dysregulation of epigenetic pathways; pharmaceutical preparations for epigenetic modulators as therapeutics; pharmaceuticals comprising small molecules for the treatment and prevention of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer's, sepsis, and restenosis; small molecule compounds for use as drug delivery agents in pharmaceuticals; small molecule compounds being pharmaceuticals for the treatment and prevention of diseases and disorders, namely, metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer's, sepsis, and restenosis in humans; small molecule pharmaceuticals for the treatment of diseases and conditions, namely, metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer's, sepsis, and restenosis; Pharmaceuticals and pharmaceutical preparations for human use for the treatment and prevention of diseases and disorders, namely, metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer's, sepsis, and restenosis; antibodies sold as a component ingredient of pharmaceuticals for the treatment of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer's, sepsis, and restenosis; diagnostic preparations for medical purposes; biological substances for human medical diagnostics and analysis for the treatment of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer's, sepsis, and restenosis; Clinical medical reagents; Biological preparations for medical purposes, namely, for the treatment of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer's, sepsis, and restenosis; pharmaceutical and veterinary preparations, agents and substances for the treatment of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer's, sepsis, and restenosis | ACTIVE | — |
| 042 | Pharmaceutical research and development of pharmaceutical preparations, medicines and vaccines; providing medical and scientific research information; Scientific research in the nature of conducting clinical trials for others; scientific and technological services, namely, scientific research, analysis, and testing services in the fields of analytical chemistry, biochemistry, medicinal chemistry, drug development, biotechnology, microbiology and molecular biology; research and design services, namely, research and development in the field of antibodies and clinical research in connection with the treatment and prevention of metabolic disorders, infectious diseases, cancer, inflammatory diseases, Alzheimer's, sepsis, and restenosis | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by MorphoSys AG
- Other trademarks owned by MorphoSys AG
- Other trademarks owned by MorphoSys AG
- Other trademarks in Class 001
- Other trademarks in Class 005
- Other trademarks in Class 042
- Similar marks named MORPHOSYS
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 21, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 21, 2025 | ECDR | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | — |
| Mar 21, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Mar 21, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Mar 21, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Mar 21, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Jun 6, 2023 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Jun 6, 2023 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Mar 21, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Mar 21, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Mar 1, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Feb 13, 2023 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Feb 10, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Feb 10, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Feb 10, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Feb 10, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Feb 1, 2023 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Feb 1, 2023 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Feb 1, 2023 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Feb 1, 2023 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jan 10, 2023 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jan 10, 2023 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jan 9, 2023 | ALIE | ASSIGNED TO LIE | — |
| Nov 11, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jun 27, 2022 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 27, 2022 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 27, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 24, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Oct 25, 2021 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 27, 2021 | NWAP | NEW APPLICATION ENTERED | — |